Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment
| Autor: | Peter Bytzer, Anna Morocutti, Peter Kennerly, Miroslav Ravic, Neil Miller, null ON BEHALF OF THE ROSE TRIAL INVESTI |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Rabeprazole Proton-pump inhibitor Gastroenterology 2-Pyridinylmethylsulfinylbenzimidazoles Double-Blind Method Internal medicine otorhinolaryngologic diseases Esophagitis Humans Medicine Enzyme Inhibitors Adverse effect Omeprazole business.industry Esophageal disease digestive oral and skin physiology Heartburn medicine.disease Dysphagia digestive system diseases Patient Satisfaction Gastroesophageal Reflux Quality of Life Female medicine.symptom business medicine.drug |
| Zdroj: | Scandinavian Journal of Gastroenterology. 41:1132-1140 |
| ISSN: | 1502-7708 0036-5521 |
| DOI: | 10.1080/00365520600615781 |
| Popis: | Gastro-oesophageal reflux disease (GORD) symptoms have a significant impact on patients' well-being. Onset of symptom relief is therefore an important consideration in GORD treatment. The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis. Secondary objectives included maintenance of sustained heartburn control, control of other GORD symptoms (e.g. acid regurgitation, epigastric pain, dysphagia), effect on quality of life, patient satisfaction with treatment, and adverse events.In this multicentre, randomized, parallel-group, double-blind, comparative study, performed in Europe and Iceland, patients with endoscopically confirmed erosive oesophagitis were randomized to receive once-daily treatment with rabeprazole 20 mg (n=358) or omeprazole 20 mg (n=359) for 7 days. Symptoms were recorded (scored on a 5-point Likert scale) twice daily by the patients on their diary cards.Median time to reach heartburn control was 1.5 days for both the rabeprazole and omeprazole groups (p0.43). The results were similar between treatments for other study parameters. Both treatments were well tolerated.Unlike previous studies, no significant differences were found between treatments with rabeprazole (20 mg) and omeprazole (20 mg) in this study. Further studies are needed to evaluate the potential benefit of fast-acting proton-pump inhibitors, such as rabeprazole, with respect to onset of symptom control in erosive GORD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|